Theramir Secures €525,000 To Propel Cancer Therapy To Clinical Phase

In a significant boost to its pioneering cancer treatment research, Theramir has successfully raised €525,000 in a bridge funding round. This capital injection is poised to support the company’s operations through the latter half of 2025, targeting a critical milestone: the initiation of clinical trials for their innovative therapy, EVmiR.

EVmiR, now patented by the European Patent Office, represents a novel approach in cancer treatment. By utilising extracellular vesicles (EVs) to deliver microRNAs (miRNAs) directly into tumours, Theramir aims to target oncoproteins—key regulators of cancer cell growth. This precision method promises fewer side effects compared to traditional treatments such as chemotherapy. The company’s technology has demonstrated efficacy in treating metastatic breast cancer and is now being tested for pancreatic and bladder cancers.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Theramir, co-founded by Marianna Prokopi-Demetriades and Costas Pitsillides in 2016, emerged from a passionate pursuit to find a cure for cancer. Their unique technology capitalises on EVs’ natural ability to transport biological information, essentially turning them into couriers that deliver tumour-suppressive messages via miRNAs. This method requires a detailed genetic profile of the patient to enhance the therapy’s precision and effectiveness, potentially offering prophylactic benefits by identifying genetic markers linked to high-risk conditions.

The latest funding round saw participation from notable investors, including Yannos Palate, a former executive at Eli Lilly, who will join Theramir’s advisory board. His extensive experience in life sciences and pharmaceutical engagement is expected to be instrumental in forging strategic partnerships with major pharmaceutical companies. Other investors include Nicosia-based family office Exerte Partners and finance and corporate lawyer Nancy Erotocritou.

Despite the challenges posed by the limited local life-sciences ecosystem in Cyprus, Theramir has managed to attract significant investor interest, raising €2.5 million in total, including €300,000 in grants. The company’s innovative approach and lower research costs compared to major biotech hubs like Boston or London have contributed to its success.

Looking ahead, Theramir is actively seeking a licensing deal with a major pharmaceutical firm to support the clinical trials, which could span up to seven years. The co-founders are optimistic about expediting the timeline through process efficiencies, projecting a market-ready therapy by 2030. In the interim, they are also exploring new revenue streams, such as using EVmiR to treat chronic malignant wounds through a project named MIRACULOUS, which has secured additional funding.

The Future Forbes Realty Global Properties

Dell’s Earnings Beat Puts The AI Trade To The Test

by THEFUTURE.TEAM

September 2, 2026

Dell Technologies has become a key stock to watch after its latest earnings report strengthened the case for continued AI infrastructure spending but failed to trigger a sustained rally.

Shares jumped more than 13% after Tuesday’s opening bell before giving back much of the gain. By late morning Wednesday, the stock was up about 5%, raising questions about whether strong AI-related earnings are still enough to drive higher valuations.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Strong Results Meet A More Skeptical Market

The reaction echoes last week’s trading in Nvidia. Its shares climbed nearly 9% after strong quarterly results and a stronger long-term outlook, only to surrender much of the advance in subsequent sessions.

That pattern has encouraged some investors to reduce exposure to AI stocks. Strong results remain evident, but markets appear less willing to reward them with sustained valuation expansion.

Dell Raises 2027 Earnings Outlook

Three months ago, Dell shares surged almost 33% after the company raised its fiscal 2027 adjusted earnings-per-share guidance by 39%. Analysts followed by lifting their own estimates, while the stock retained most of its gains.

This time, Dell raised fiscal 2027 earnings guidance to $25.50 from $17.90, an increase of about 42.5%. Street consensus rose nearly 29% overnight, yet the stock was up only about 5% in Wednesday trading.

The weaker share-price reaction suggests investors are applying a more cautious valuation to Dell than they did in May.

AI Exposure Faces Greater Caution

We have been raising cash for the Club as the AI trade has become more volatile and less predictable. Tuesday’s decision to exit Corning increased our cash position to about 15%.

If capital is redeployed, it would likely favor more defensive areas outside AI. That reflects greater caution over valuations and positioning rather than a rejection of the AI investment theme.

Dell’s Trading Could Set The Tone

A further rise in Dell shares would suggest investors remain willing to increase AI exposure, while a flat performance would point to greater valuation discipline. A decline could indicate that much of the earnings upside is already priced in.

Dell’s report, along with Broadcom’s results due Wednesday evening, could still improve sentiment across the group. If investors continue to discount strong AI earnings, however, the case for a more defensive approach will strengthen.

For now, Dell offers a real-time test of whether strong AI-related earnings can continue to drive valuations higher as investor caution increases.

Breaking news